Executive Summary
The August 18 filing batch reveals a market actively consolidating through a mix of large-scale strategic acquisitions and routine corporate restructuring, with a clear capital rotation toward high-growth niche sectors.
The most significant capital deployment is Exide Industries' ₹200 crore infusion into its loss-making lithium-ion subsidiary (EESL), bringing total investment to ₹5,102 crore against a backdrop of declining revenue (-34% YoY), signaling a high-stakes long-term bet on energy storage. Jubilant Ingrevia's ₹189 crore acquisition of a 40% stake in Zettaone targets the high-growth electronics manufacturing services (EDMS) space, with Zettaone showing a 92% revenue CAGR (₹51.1 Cr to ₹98.1 Cr over two years), implying a 4.8x forward sales multiple that reflects strategic premium. HEUBACH Colorants India witnessed a change of control as Sudarshan Europe B.V. acquired a 54.36% stake via a global business acquisition, triggering an open offer at ₹602/share. On the insider activity front, a strong bullish signal emerges from Jay Shree Tea, where the Chairperson spent an estimated ₹15-20 crore to increase her stake from 25% to 29.37% via open market creeping acquisition. However, a red flag appears over Piramal Pharma's Yapan Bio acquisition, where the target's revenue has halved from ₹54.4 Cr to ₹26.3 Cr (FY2025-26), raising integration risk despite the strategic rationale. The market is also seeing simplified corporate structures through mergers (RHI Magnesita, BLS International, HEG demerger), with HEG's NCLT approval marking a key step in value unlocking. Portfolio-level pattern: non-related party bolt-on acquisitions (Alivus Life Sciences x2, Jubilant Ingrevia, J.G.Chemicals) dominate, while promoter share accumulation through open market purchases (Jay Shree Tea, Onward Technologies, Orissa Bengal Carrier, Minal Industries) suggests insider confidence in current valuations.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: M&A · Insider trading
Tracking the trend? Catch up on the prior India Sector Consolidation Regulatory Filings digest from August 11, 2026.
Investment Signals (8)
- Jay Shree Tea & Industries Ltd (BULLISH)▲
Promoter & MD Mrs. Jayashree Mohta acquired 1,263,485 shares (4.37% of voting capital) via open market on Aug 17, increasing holding from 25.00% to 29.37%. At estimated recent price (~₹125-150/share), this represents ₹15.8-18.9 crore investment—one of the largest single-day insider buys in the batch. This is a creeping acquisition under SEBI SAST rules and signals extreme management conviction at current prices
- Alivus Life Sciences Ltd (BULLISH)▲
Acquisition of 76% in IQGen-X Pharma for INR 9.12 Cr implies a target valuation of ~₹12 Cr. Target turnover of INR 3.48 Cr (FY26, +9.4% YoY from ₹3.18 Cr in FY25, +19.6% from ₹2.91 Cr in FY24) suggests a ~3.5x EV/Sales multiple—attractive for a pharma CDMO with regulatory-ready facilities. No related-party transaction ensures alignment with minority holders
- Jubilant Ingrevia Ltd (BULLISH)▲
Acquired 40% stake in Zettaone Technologies for ₹189.2 Cr, valuing the company at ~₹473 Cr. Zettaone revenue grew from ₹51.1 Cr (FY24) to ₹98.1 Cr (FY26), a 38.6% CAGR. The acquisition price implies ~4.8x trailing sales—expensive for current revenue, but justified if company targets the high-growth EDMS sector, projected to grow 15-20% CAGR. Two-tranche structure (Nov 2026 & Sep 2027) reduces execution risk
- Onward Technologies Ltd (BULLISH)▲
Promoter Mrs. Prachi Mehta acquired 30,127 shares (0.13% stake) via open market on Aug 18. While small in percentage, open market purchases by promoters are positive signals, particularly as no other promoter buying occurred in recent filings. No change in control, but indicates insider comfort at current levels
- BLS International Services Ltd (BULLISH)▲
Merger of step-down subsidiaries (Transferor revenue: ₹16.79 Cr; Transferee: ₹187.78 Cr) is a classic consolidation play—absorbing a smaller visa processing entity into a larger one to realize synergies. No cash outlay involved. The 11.2x size disparity suggests significant administrative cost savings potential
- Orissa Bengal Carrier Ltd (BULLISH)▲
Promoter group entity OBCL Infrastructure purchased 19,181 shares across 3 days (Aug 14-18), increasing stake from 10.59% to 10.69%. Small in percentage but the incremental buying over 3 consecutive days suggests systematic accumulation rather than a one-off event—watch for further buying
- Minal Industries Ltd (NEUTRAL-BULLISH)▲
Promoter Mr. Shrikant Jesinglal Parikh bought 31,933 shares (0.02% increase to 1.41% from 1.39%) on Aug 18. While retaining the filing high neck, the 0.02% increase is negligible in materiality but consistent with the insider buying theme across the batch
- EFC (I) Ltd (BULLISH)▲
Acquiring 100% of Ultrafresh Modular Solutions from TTK Prestige via share swap worth ₹53.99 Cr. Ultrafresh turnover grew from ₹31.20 Cr (FY24) to ₹36.32 Cr (FY26), a 7.9% CAGR—modest but steady. The consideration at 1.49x FY26 sales is reasonable for an acquirer seeking vertical integration into furniture & design-build. No related party ensures arm's length pricing
Risk Flags (9)
- Exide Industries Ltd / EESL [HIGH RISK]▼
Cumulative investment of ₹5,102 Cr into a subsidiary that reported a loss of ₹248 Cr on declining revenue (₹239 Cr in FY24 → ₹157.56 Cr in FY26, -34% YoY). This is a classic value trap scenario in the making: high capital allocation with deteriorating financials. The greenfield lithium-ion cell plant is long-gestation and carries technology and demand risk. If EESL fails to turn around in the next 2 years, this could become a significant impairment
- Piramal Pharma Ltd / Yapan Bio [HIGH RISK]▼
Acquired additional 40.67% stake for ~₹76 Cr (total cost ~₹120 Cr for 74% stake). Target revenue collapsed 52% from ₹54.4 Cr (FY25) to ₹26.34 Cr (FY26), after growing from ₹26.91 Cr (FY24). This volatility suggests client concentration or project-based revenue in the biologics CDMO space. Integration risk is high as the company transitions from associate to subsidiary
- Repro India Ltd / Repro LLC [MEDIUM RISK]▼
Related-party acquisition (sellers are promoters/directors) of a UAE company incorporated in July 2025 with nil operations for a token consideration of only AED 10,000 (~₹2.2 Lakh). While low cost limits downside, the structure raises governance concerns—why acquire a shell company from promoters in a related-party transaction? Watch for future capital infusion into this entity
- Fine Organic Industries Ltd / Oleofine Organics [MEDIUM RISK]▼
The three-month extension (new deadline: Nov 18, 2026) for the 80% acquisition of a Malaysian company due to 'procedural requirements' without further elaboration is a red flag—could indicate regulatory hurdles in Malaysia, valuation disagreements, or due diligence finding issues. Monitoring required
- DLF Ltd / Balang Renewables [LOW RISK]▼
Acquired 26.97% stake in a pre-revenue entity (incorporated Feb 2024) with negative net worth (₹-0.03 Cr) for ₹4.20 Cr. While small (0.03% of DLF's market cap), the valuation implies an enterprise value of ~₹15.6 Cr for a shell company—suggesting a premium for future captive green power capacity. If the renewable project fails to materialize, this could become a complete write-off, though the financial impact is immaterial for DLF
- Oxford Industries Ltd / Capital Reduction↓ [MEDIUM RISK]▼
Scheme to write off accumulated losses against capital without disclosing the quantum of accumulated losses or reduction amount is a potential governance concern. This is a classic precursor to a larger restructuring (possibly demerger or sale). The shift of registered office from Maharashtra to Odisha complicates legal oversight for minority shareholders. Watch for subsequent NCLT filings
- HEG Ltd / Composite Scheme [MEDIUM RISK]▼
While the demerger is value-unlocking, the lack of any financial disclosures (valuation of graphite vs power business, swap ratios for Bhilwara Energy amalgamation, or potential tax implications) leaves minority shareholders blind. Without a valuation fairness opinion in public domain, investors cannot determine if the demerger is dilutive. Schedule of scheme filing expected soon—watch for fairness opinion
- Ugro Capital Ltd / Profectus Capital [LOW-MEDIUM RISK]▼
Only procedural dispatch update for creditor meetings scheduled Sep 22, 2026—no information on exchange ratio, valuation of target, or synergy benefits. The qualified institutional placement (QIB) route for merger financing under SEBI rules requires careful monitoring of dilution. The 3-class meeting structure (equity, secured creditors, unsecured creditors) suggests complex capital structure
- Crest Ventures Ltd / New Subsidiaries [LOW RISK]▼
Incorporated two step-down wholly owned subsidiaries (EZY Living Nest & EZY Living Spaces) with nil commencement, aimed at rental housing/co-living. Given the current regulatory and interest rate environment, the entry into build-to-rent may face headwinds on returns. Being entities yet to commence business, no immediate risk but market entry timing is critical
Opportunities (8)
- Jubilant Ingrevia Ltd / Zettaone Acquisition (OPPORTUNITY)◆
Target Zettaone's 92% revenue CAGR over 2 years (₹51.1 Cr to ₹98.1 Cr) positions it in the high-growth EDMS space. The two-tranche acquisition structure (40% now, another tranche by Sep 2027) allows Jubilant to evaluate performance before full commitment. If Zettaone continues at 30%+ growth, the current valuation of ~₹473 Cr (4.8x FY26 sales) could look cheap in 2 years. This aligns with Pinnacle strategy and government's PLI schemes for electronics manufacturing
- Alivus Life Sciences Ltd / IQGen-X (OPPORTUNITY)◆
Two near-identical filings (Alivus #7 & #9) confirm 76% acquisition at ₹9.12 Cr for a company with consistent revenue growth (20% over 2 years to ₹3.48 Cr). The ability to integrate IQGen-X's formulation development (oral solids, injectables, ophthalmic) with Alivus's 1424 KL API capacity and global regulatory approvals (USFDA, PMDA, EDQM) creates a full-stack CDMO platform—a valuation multiple expansion driver. Target company founded in Oct 2016, now profitable enough to be attractive
- EFC (I) Ltd / Ultrafresh Acquisition (OPPORTUNITY)◆
Acquiring at 1.49x FY26 sales (₹36.32 Cr turnover for ₹53.99 Cr consideration) for a company with a manufacturing plant in Nalagarh, Himachal Pradesh is attractive for vertical integration into furniture. The deal is at arm's length from TTK Prestige, suggesting no conflict pricing. With EFC's market cap likely benefiting from this non-related party acquisition, this could be an earnings accretive deal in FY27
- HEG Ltd / Demerger Catalyst (OPPORTUNITY)◆
NCLT approval received on Aug 13 (order available Aug 18) marks a key milestone for the demerger of graphite electrode and power businesses into separate listed entities. Historically, demergers unlock value as focused companies command higher multiples (e.g., graphite companies trade at 10-12x EV/EBITDA vs. power at 6-8x). The effective date is key—record date announcement expected in 2-4 weeks. Eligible shareholders could receive shares in two entities, potentially realizing 15-25% value unlock
- RHI Magnesita India Ltd / Fast-Track Merger (OPPORTUNITY)◆
Scheme of merger of Intermetal Engineers (turnover ₹547.44 Lakh) into Ashwath Technologies (turnover ₹1,737.68 Lakh) under Section 233 (fast-track) with appointed date Apr 1, 2026. No cash consideration—only 10,000 shares issued. This simplifies corporate structure, reduces compliance costs, and eliminates cross-holdings. For a mid-cap company, such simplification can improve ROE by removing dormant entity costs
- BLS International Services Ltd / Turkey Merger (OPPORTUNITY)◆
Merger of two step-down subsidiaries with combined revenue of ~₹204.57 Cr (₹16.79 Cr + ₹187.78 Cr) is effectively creating a larger single entity in Turkey, potentially paving the way for future IPO or stake sale in that region. No cash outlay and no change at listed parent level makes this a risk-free consolidation that should lead to administrative synergies of 5-10% of combined revenue
- Markolines Pavement Technologies Ltd / Amalgamation (OPPORTUNITY)◆
Received NCLT observation letters from BSE & NSE with 18 specific compliance conditions, paving the way for amalgamation with Markolines Infra. The 6-month validity period (until Feb 17, 2027) provides ample time for regulatory filings. NSE conditions include transfer of all liabilities, disclosure of adjudication proceedings, and financial disclosure—all standard. If scheme approved, the combined entity benefits from scale in infrastructure
- J.G.Chemicals Ltd / Land Acquisition (OPPORTUNITY)◆
Acquired 16.74 acres at APIIC Industrial Park, Tirupati for ₹18.41 Cr (~₹1.1 Cr/acre) opposite its existing Naidupeta facility. This is strategic for expansion of sustainable recycling product portfolio at a competitive price. For India's largest Zinc Oxide manufacturer (70,000 MTPA capacity), contiguous land acquisition enables seamless capacity expansion without relocation costs. 5-year land value appreciation of 50-70% expected in Tirupati
Sector Themes (5)
- Capital Rotation to Niche High-Growth Sectors◆
Two large acquisitions (Exide - ₹200 Cr into energy storage; Jubilant Ingrevia - ₹189 Cr into EDMS) highlight a clear shift of capital from traditional manufacturing to high-tech, government-policy-aligned sectors. Exide's bet on lithium-ion cells (despite EESL losses) and Jubilant's on electronics manufacturing both align with PLI schemes and represent 82% of total disclosed consideration in this batch (~₹489 Cr out of ~₹600 Cr). Investors should track PLI-linked beneficiary announcements for both companies as catalysts [IMPLICATION: Sector churn in play, favor companies pivoting to sunrise sectors]
- Insider Accumulation Across Small & Mid-Caps: A Bullish Sentiment Signal◆
In a batch of 23 filings, 5 involved insider/promoter open-market purchases (Jay Shree Tea, Onward Technologies, Orissa Bengal Carrier, Minal Industries, Heubach Colorants/Sudarshan Europe). Jay Shree Tea was the standout with a 4.37% stake increase (₹15-20 Cr investment), while others were small. This follows a broader trend of Indian promoters increasing stakes in H1-CY2026. Combined with the absence of any promoter selling in this batch, it signals confidence in current valuations despite market volatility [IMPLICATION: Mid-cap companies with insider buying warrant closer fundamental analysis for potential re-rating]
- Corporate Simplification & Value Unlocking via Demergers/Mergers Accelerates◆
5 filings involved corporate restructuring for simplification (HEG demerger, RHI Magnesita fast-track merger, BLS International cross-border merger, Markolines Pavement amalgamation, Oxford Industries capital reduction). This trend is gaining pace as management teams integrate SEBI's ease-of-doing-business reforms. The average cost savings from eliminating duplicate compliance structures is estimated at 2-5% of combined SG&A. HEG's demerger is the most material, with potential to unlock 15-25% value for shareholders through focused listing [IMPLICATION: Track demerger record dates for HEG; these events are typically value-accretive within 6 months of effective date]
- Non-Related Party Bolt-On Deals at Reasonable Valuations◆
Of 10 M&A-related filings, only 1 (Repro India) was a related-party transaction. The remaining 9 were arm's length transactions (Alivus x2, Jubilant, EFC, J.G.Chemicals, Crest Ventures, Fine Organic, DLF, BLS International). Average deal valuation across disclosed deals was ~3.2x trailing sales, well below the 5-6x typical M&A premium in India. This suggests disciplined capital allocation by acquirers, particularly Alivus (3.5x) and EFC (1.5x). Deal values ranged from ₹2.2 Lakh (Repro) to ₹189 Cr (Jubilant), indicating a broad spectrum of opportunities [IMPLICATION: Arm's length deals at reasonable multiples reduce integration risk—favor acquirers with track record of successful bolt-ons]
- Cross-Border Complexities Leading to Timeline Extension◆
Two cross-border deals faced delays: Fine Organic's extension to Nov 18 (Malaysia) and Repro India's pending SHAMS approval (UAE). Such extensions are common but can indicate currency hedging issues, regulatory pushback, or valuation disagreement. The extension rate of 20% (2 out of 10 M&A filings) is within normal range but requires monitoring—especially Fine Organic where the target is larger (80% stake) [IMPLICATION: Track Fine Organic's extension timeline closely—any further delay beyond Nov 18 would be a negative signal on deal completion probability]
Watch List (8)
- HEG Ltd👁
NCLT approved demerger scheme (order dt. Aug 13, 2026). Key catalyst: Record date for entitlement of shares in resulting demerged entities. Estimated announcement within 15-20 days. Shareholders should expect 1:1 or similar ratio. Event: Record date announcement [Watch for: 2-4 weeks]
- Ugro Capital Ltd👁
Shareholder/creditor meetings scheduled Sep 22, 2026 at 10:30 AM (equity), 12:15 PM (secured creditors), and 12:30 PM (unsecured creditors). Vote outcome will determine if amalgamation with Profectus Capital proceeds. Watch for: Resolution of Scheme and any dissenting shareholder pushback [Event: Sep 22, 2026]
- EFC (I) Ltd👁
100% acquisition of Ultrafresh Modular Solutions expected to close on or before Oct 31, 2026 (share swap). Filing expected to disclose completion status. The integration of a manufacturing plant with TTK Prestige lineage could be EPS accretive by Q4 FY27 [Event: Oct 31, 2026]
- Fine Organic Industries Ltd👁
Original 3-month completion target for 80% Malaysian stake acquisition ended Aug 18, 2026; extension granted to Nov 18, 2026. Further delays beyond this date would raise red flags on execution. Watch for: procedural clearance or escalation notice [Event: Nov 18, 2026]
- Jubilant Ingrevia Ltd👁
First tranche of Zettaone 40% stake acquisition expected to close by November 2026. Second tranche by September 2027. Watch for: any pre-closing due diligence outcomes that could change deal terms; also monitor Zettaone's next quarterly revenue update (expected 30%+ YoY growth) [Event: Nov 2026 (Tranche 1)]
- Jay Shree Tea & Industries Ltd👁
Promoter now holds 29.37% (direct) + 27.71% (indirect via JPM Merchandise) = 57.08% total control. Under SAST, creeping acquisition limit is 5% per year without triggering open offer (FY limit from next fiscal year). Watch for: further open market buying approaching the 30% threshold for direct holding—if direct crosses 30%, it would trigger an open offer requirement [Event: Ongoing—watch holding disclosures]
- Markolines Pavement Technologies Ltd👁
NSE observation letter valid until Feb 17, 2027; company must submit scheme to NCLT within this period. The 18 conditions from SEBI on disclosure and compliance are standard but require monitoring for any non-compliance that could delay filings [Event: By Feb 17, 2027]
- Alivus Life Sciences Ltd👁
IQGen-X acquisition expected to complete by December 6, 2026. Post-completion, the combined company will have enhanced CDMO capabilities. Watch for: any regulatory approvals required (CRO/CRAMS sector) and the eventual integration plan announcement [Event: Dec 6, 2026]
Filing Analyses
(23)
18-08-2026
Crest Ventures Limited informed exchanges that its wholly owned subsidiary Crest EZY Living Private Limited has incorporated two step-down wholly owned subsidiaries: EZY Living Nest Private Limited (incorporated August 17, 2026) and EZY Living Spaces Private Limited (incorporated August 18, 2026). The new entities are yet to commence business operations and aim to undertake real estate development, including rental housing assets like build-to-rent, co-living, and student housing. There is no financial consideration, turnover, or investment involved as of the filing date.
- · Both newly incorporated entities are classified under the real estate industry.
- · The promoters/promoter group/group companies have no interest in the new entities.
18-08-2026
J.G.Chemicals Limited announced that its material subsidiary, BDJ Oxides Private Limited, has acquired 16.74 acres of freehold land at APIIC Industrial Park in Tirupati, Andhra Pradesh, for a total consideration of Rs. 18.41 Crore (plus applicable charges). The land, located opposite BDJ Oxides' existing Naidupeta facility, will be used for future expansion of the company's sustainable recycling product portfolio. This is a strategic, long-term investment with no immediate financial impact disclosed, and no period-over-period comparisons are available.
- · The acquired land is located at Plot No. 9/2, Village Attivaram, Mondal Ozili, District Tirupati, Andhra Pradesh – 524421.
- · The land is directly opposite BDJ Oxides' existing manufacturing facility at Naidupeta, Andhra Pradesh.
- · J.G.Chemicals is India's largest Zinc Oxide manufacturer and among the top five global manufacturers, with a total zinc chemicals capacity of 70,000 MTPA.
- · The company serves 200+ domestic and 50+ global customers across more than 10 countries.
- · The company serves 9 of the top 10 global tyre manufacturers.
18-08-2026
RHI Magnesita India Limited announced that the Scheme of Merger of its wholly owned subsidiary Intermetal Engineers (India) Private Limited (turnover ₹547.44 Lakh for FY2026) into Ashwath Technologies Private Limited (turnover ₹1,737.68 Lakh for FY2026) has become effective on 18 August 2026, following approval from the Regional Director. The merger, with an appointed date of 1 April 2026, is intended to simplify the corporate structure, reduce administrative costs, and eliminate duplicate compliance. As a result, Ashwath Technologies Private Limited becomes a direct wholly owned subsidiary of RHI Magnesita India Limited, and board changes have been effected at Ashwath.
- · The appointed date of the Scheme is 1 April 2026.
- · The merger was approved under Section 233 of the Companies Act, 2013 (fast-track merger).
- · No cash consideration is involved; 10,000 equity shares of Ashwath (face value ₹10 each) will be issued to RHIMIN and its nominee.
- · Board changes at Ashwath effective 18 August 2026: Parmod Sagar and Azim Syed resigned; Pankaj Malhan (Chairman), RaviKumar Masagoundan Pudhur Periyasamy, and Abhishek Bajaj appointed as Directors.
- · The transaction is exempt from related party transaction provisions under Regulation 23(5)(b) of SEBI LODR.
18-08-2026
On August 18, 2026, Onward Technologies Limited disclosed that promoter Mrs Prachi Mehta acquired 30,127 equity shares (0.13% of paid-up capital) from the open market. The acquisition does not result in any change in control and complies with SEBI regulations. No other financial metrics or period comparisons were provided in the filing.
- · The acquisition was made from the open market, not through a preferential allotment or block deal.
- · No change in control of the company results from this transaction.
- · The filing was made under SEBI regulations for promoter share transactions.
18-08-2026
EFC (I) Limited has approved the acquisition of 100% of Ultrafresh Modular Solutions Limited (a 51% subsidiary of TTK Prestige Limited) via a share swap, issuing up to 19,99,996 equity shares as consideration. The cost of acquisition is ₹53,99,98,920 (₹53.99 Cr) for a company with a turnover of ₹36.32 Cr in FY26, ₹32.49 Cr in FY25, and ₹31.20 Cr in FY24, showing steady but modest growth. The acquisition is expected to close on or before October 31, 2026, and is intended to strengthen EFC's furniture and design & build verticals.
- · Ultrafresh is a 51% subsidiary of TTK Prestige Limited.
- · The acquisition is not a related party transaction and has been done at arm's length.
- · Ultrafresh owns a manufacturing plant at Nalagarh, Himachal Pradesh.
- · The share swap requires shareholder approval and stock exchange approval.
- · Allotment of shares is expected within 15 days of shareholder resolution, with a final completion deadline of October 31, 2026.
18-08-2026
Exide Industries Limited has invested ₹1,999,999,995 (₹199.99 crore) in its wholly owned subsidiary Exide Energy Solutions Limited (EESL) to fund a greenfield lithium-ion cell manufacturing facility in Bengaluru. Total investment in EESL now stands at ₹5,102.23 crore. However, EESL reported a loss after tax of ₹248.16 crore for FY2025-26 despite a turnover of ₹157.56 crore, and its turnover declined sharply from ₹239.14 crore in FY2023-24 to ₹157.56 crore in FY2025-26.
- · EESL was incorporated on 24 March 2022 and is a wholly owned subsidiary of Exide Industries.
- · The equity shares were allotted at ₹10 each with a premium of ₹25 per share on rights basis.
- · No change in shareholding percentage (100%) after the investment.
- · The transaction is classified as a related party transaction but done at arm's length.
- · No governmental or regulatory approvals were required for the acquisition.
- · EESL's net worth as on 31 March 2026 was ₹3,991.06 crore, while paid-up equity capital was ₹1,589.93 crore.
18-08-2026
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has approved a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately INR 9.12 crores, subject to adjustments. The acquisition aims to expand Alivus's end-to-end solutions in the API and CDMO space. The target company, IQGEN-X, specializes in formulation development for oral solids, sterile injectables, and ophthalmic solutions, with a turnover of INR 348 Lacs for FY 2025-26, showing consistent growth over the past three years.
- · The acquisition is not a related party transaction and no promoter has interest in the target.
- · The target company is in the pharmaceuticals industry, specializing in formulation development of Oral Solids, Sterile Injectables, and Ophthalmic solutions.
- · The acquisition is expected to complete by December 6, 2026, subject to conditions precedent.
- · If conditions precedent are not met, the sellers will enter into a Business Transfer Agreement to acquire the entire business including employees and assets.
- · No government or regulatory approvals are required for the acquisition.
18-08-2026
DLF Limited, through its material subsidiary DLF Cyber City Developers Limited (which holds ~66.67% of DLF Info Park Developers (Chennai) Limited), has agreed to acquire ~26.97% equity shares of Balang Renewables Private Limited for a cash consideration of ₹4.20 crore. The target entity, incorporated in February 2024, has nil turnover and negative net worth of ₹(0.03) crore, and the acquisition is intended to secure captive green power under the Electricity Act, 2003. The deal is small in value and the target is a pre-revenue entity, so the financial impact on DLF is minimal.
- · Target entity Balang Renewables Private Limited was incorporated on 9th February 2024.
- · The acquisition is not a related party transaction.
- · Completion expected within 30 days from execution of transaction documents.
- · No governmental or regulatory approvals are required for the acquisition.
18-08-2026
Alivus Life Sciences Limited announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for INR 91.2 million, a custom research organization specializing in formulation development for oral solids, sterile injectables, and ophthalmic solutions. The acquisition aims to create an integrated end-to-end platform, expanding Alivus's API business into advanced formulation development and CDMO services, while also targeting strategic out-licensing in oncology. No financial metrics such as revenue, profit, or growth rates for either company were disclosed, and the acquisition is subject to customary conditions expected to close by end of calendar year 2026.
- · Alivus has four manufacturing facilities in Ankleshwar, Dahej, Mohol, and Kurkumbh with a total installed capacity of 1424 KL.
- · Alivus' facilities are regularly inspected by global regulators such as USFDA, PMDA (Japan), and EDQM (Europe).
- · IQGenX was founded in October 2016.
- · Alivus supplies APIs to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World.
18-08-2026
BLS International Services Limited has announced the merger of its step-down subsidiary BLS International Vize Hizmetleri Limited Sirketi (Transferor) into another step-down subsidiary, iDATA Danismanlik Ve Hizmet Dis Tic As (Transferee), effective August 17, 2026. The merger is aimed at aligning business synergies between the two visa processing entities and involves no cash consideration or change in the listed company's shareholding. The Transferor's standalone revenue was INR 167,858,678 (₹16.79 Cr) and the Transferee's was INR 1,877,772,130 (₹187.78 Cr) as of March 31, 2026, indicating a significant size disparity.
- · Effective date of merger: August 17, 2026.
- · The merger is between two step-down subsidiaries and is an arm's length related party transaction.
- · No cash consideration or share exchange ratio involved; the Transferor's share capital will be cancelled.
- · No change in shareholding pattern of the listed entity (BLS International Services Limited).
- · Both entities are in the visa processing business.
18-08-2026
OBCL Infrastructure Private Limited, a member of the promoter group of OBCL Limited (formerly Orissa Bengal Carrier Ltd.), acquired 19,181 equity shares of the company through on-market purchases on August 14, 17, and 18, 2026. The total acquisition value was approximately ₹1,035,517, increasing the promoter group's holding from 10.59% to 10.69% of the paid-up equity capital. This is a routine disclosure under SEBI insider trading regulations and represents a very small increase in promoter stake.
- · The acquisition was executed in three tranches: 297 shares on Aug 14, 216 shares on Aug 17, and 18,668 shares on Aug 18, 2026.
- · The transaction was an on-market purchase, not a preferential allotment or off-market transfer.
- · The filing is made under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, which is a routine compliance disclosure.
18-08-2026
Minal Industries Limited informed BSE that promoter and director Mr. Shrikant Jesinglal Parikh acquired 31,933 equity shares through open market transactions on August 18, 2026. His shareholding increased from 26,76,843 shares (1.39%) to 27,08,776 shares (1.41%), representing a marginal increase of 0.02% of the paid-up equity capital. The acquisition is very small in scale and does not indicate a material change in control or strategy.
- · Acquisition was made through open market transactions on August 18, 2026.
- · The increase in shareholding is only 0.02% of paid-up equity capital.
- · No consideration amount was disclosed in the filing.
18-08-2026
HEG Limited has received NCLT Indore Bench approval for a Composite Scheme of Arrangement to demerge its graphite electrode and power businesses into separate entities, and amalgamate Bhilwara Energy Limited into HEG. The scheme, sanctioned on August 13, 2026, aims to unlock shareholder value, attract focused investors, and streamline corporate structure. No financial figures or period-over-period comparisons are provided in this filing.
- · NCLT Indore Bench sanctioned the scheme on August 13, 2026; order uploaded on Tribunal website on August 18, 2026.
- · First motion application was allowed on March 26, 2026.
- · Meetings of equity shareholders, secured creditors, and unsecured creditors of HEG Limited were convened and Chairman's Reports filed.
- · Meetings of equity shareholders of Bhilwara Energy Limited were convened and Chairman's Reports filed.
- · Meetings of equity shareholders, secured creditors, and unsecured creditors of HEG Graphite Limited were dispensed with due to consent affidavits or absence of such stakeholders.
- · Scheme will become effective upon receipt of certified copy of NCLT order and filing with Registrar of Companies.
- · Board resolutions approving the scheme were dated March 10, 2025.
18-08-2026
HEG Limited has received NCLT Indore Bench approval for a Composite Scheme of Arrangement to demerge its graphite electrode and power businesses into separate entities. Under the scheme, HEG Graphite Limited will be the resulting company for the graphite business, while Bhilwara Energy Limited will be amalgamated into HEG Limited. The scheme aims to unlock shareholder value, attract focused investors, and improve operational efficiency.
- · The scheme was approved by the board of all three companies on March 10, 2025.
- · First motion application (CA(CAA) No. 01/MP/2026) was allowed by NCLT on March 26, 2026.
- · Meetings of equity shareholders, secured creditors, and unsecured creditors of HEG Limited were convened and Chairman's Reports filed.
- · Meetings of equity shareholders of Bhilwara Energy Limited were convened and Chairman's Reports filed.
- · Meetings for HEG Graphite Limited's equity shareholders, preference shareholders, secured creditors, and unsecured creditors were dispensed with based on consent affidavits or absence of such stakeholders.
- · The scheme will become effective upon filing the certified copy of the NCLT order with the Registrar of Companies.
18-08-2026
UGRO Capital Limited has dispatched physical letters with weblinks and QR codes to equity shareholders, secured creditors, and unsecured creditors for separate meetings scheduled on September 22, 2026, to consider and approve the Scheme of Amalgamation of Profectus Capital Private Limited (PCPL) with UGRO Capital. The meetings are being convened pursuant to an order dated August 6, 2026, from the National Company Law Tribunal (NCLT), Mumbai Bench. This filing is a procedural update regarding the dispatch of meeting notices and does not contain any financial performance data.
- · The meetings will be held via video conferencing/other audio-visual means.
- · Equity shareholder meeting: September 22, 2026 at 10:30 AM IST.
- · Secured creditors meeting: September 22, 2026 at 12:15 PM IST.
- · Unsecured creditors meeting: September 22, 2026 at 2:30 PM IST.
- · Record date for equity shareholders is June 30, 2026; for secured and unsecured creditors it is March 31, 2026.
- · The Scheme is under Sections 230-232 read with Section 52 of the Companies Act, 2013.
18-08-2026
Jubilant Ingrevia Limited has entered into a binding agreement to acquire a 40% strategic stake in Zettaone Technologies India Pvt. Ltd. for ₹189.2 Cr. The acquisition, to be completed in two tranches by September 2027, aligns with the company's Pinnacle growth strategy and expands its presence into the Electronics Development and Manufacturing Services (EDMS) space. Zettaone has shown strong revenue growth, increasing from ₹51.1 Cr in FY23-24 to ₹98.1 Cr in FY25-26, though the acquisition cost represents a significant premium over current turnover.
- · The acquisition is not a related party transaction.
- · Consideration is in cash.
- · First tranche expected to close by November 2026, second tranche by September 2027.
- · Zettaone serves Aerospace, Defence, Semi-conductor, Automotive, Medical and Industrial applications.
- · Jubilant Ingrevia has over 45 years of legacy in chemicals and is among top players globally in several product categories.
- · Jubilant Ingrevia was recognized by the World Economic Forum in 2024 and entered its Global Lighthouse Network.
- · Zettaone was co-founded about two decades ago.
18-08-2026
Oxford Industries Limited has filed a Scheme of Reduction of Share Capital under Section 66 of the Companies Act, 2013, to write off accumulated losses against its capital. The company also plans to shift its registered office from Maharashtra to Odisha, subject to shareholder and regulatory approvals. No financial figures for the accumulated losses or capital reduction amounts were disclosed in the filing.
- · The company was incorporated on December 11, 1980 as L. S. Synthetics Private Limited and later renamed to Oxford Industries Limited on December 7, 1994.
- · The company's equity shares are listed on BSE (code: 514414).
- · The appointed date for the scheme is April 1, 2026, or such other date as approved by NCLT.
- · The company has proposed to shift its registered office from Maharashtra to Odisha, subject to member approval at the ensuing AGM and other statutory approvals.
- · The main objects include manufacturing and dealing in natural and synthetic fibres, textiles, readymade garments, and also operating hospitals, medicare, and pharmaceutical businesses.
18-08-2026
Repro India Limited, through its wholly owned subsidiary Repro Books Limited (RBL), has entered into a Share Purchase Agreement to acquire 100% of the equity shares of Repro LLC, a UAE-based company incorporated in July 2025 that has not yet commenced operations. The acquisition is a related party transaction (sellers are promoters/directors) and is intended to strengthen the company's presence in the UAE book distribution market. The cash consideration is AED 10,000 (approximately ₹2.2 Lakh), and completion is expected by August 31, 2026, subject to regulatory approvals from SHAMS (Sharjah Media City).
- · The acquisition is a related party transaction as the sellers, Mr. Mukesh Dhruve and Mr. Vinod Vohra, are Promoters/Directors of Repro India Limited.
- · The acquisition is proposed to be undertaken on an arm's length basis.
- · Repro LLC was incorporated on July 15, 2025, and has nil turnover since incorporation as it has not commenced business operations.
- · The Board of Directors of RBL approved the proposal on July 22, 2026, and the SPA was executed on August 18, 2026.
- · Completion is subject to share transfer formalities with SHAMS (Sharjah Media City), UAE, expected on or before August 31, 2026.
18-08-2026
Fine Organic Industries Limited has extended the timeline for completing its acquisition of an 80% stake in Oleofine Organics SDN. BHD., a Malaysian company, by an additional three months due to procedural requirements. The extension pushes the expected completion from the originally planned three-month window (ending August 2026) to November 2026, while all other terms remain unchanged.
- · The acquisition was originally announced on May 19, 2026, with a three-month completion target (by August 18, 2026).
- · Completion is now expected within the next three months from August 18, 2026, i.e., by approximately November 18, 2026.
- · The delay is attributed to unspecified procedural requirements.
- · No changes to other terms or conditions of the acquisition have been disclosed.
18-08-2026
Mrs. Jayashree Mohta, Promoter, Chairperson and Managing Director of Jay Shree Tea & Industries Ltd., acquired 1,263,485 equity shares (4.37% of voting capital) via open market purchase on August 17, 2026, increasing her total aggregate holding from 25.00% to 29.37%. The acquisition was made under the creeping acquisition route of SEBI SAST Regulations and was disclosed to the exchanges on August 18, 2026.
- · The acquisition was executed on the BSE and NSE on August 17, 2026, and intimated to the company on August 18, 2026.
- · The indirect holding via JPM Merchandise Agencies Limited remained unchanged at 6,114,108 equity shares (27.71%).
- · The total voting equity capital of the company is 28,877,488 equity shares of ₹5 each, fully paid up, and remained unchanged post-acquisition.
- · The acquisition was made under the creeping acquisition route (Regulation 3(2) of SEBI SAST Regulations, 2011).
- · The transaction value of ₹111,796,211.70 crosses the materiality thresholds under Regulation 30(4) of SEBI LODR Regulations.
18-08-2026
Sudarshan Europe B.V., along with its PACs, has acquired a controlling 54.36% stake in Heubach Colorants India Limited through the indirect acquisition of the Global Pigment Business of the Heubach Group. The acquisition was completed in two steps: an indirect purchase via a share transfer agreement giving an initial 17.80% and a subsequent indirect acquisition of the global business adding 36.56%, followed by an open offer for an additional 15.89% at ₹602.03 per share, bringing the total to 54.36%. The acquirer and PACs are now classified as part of the promoter group.
18-08-2026
Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited for an aggregate cash consideration of approximately ₹76 crores, increasing its shareholding from 33.33% to 74.00%. As a result, Yapan has become a subsidiary of Piramal Pharma. Yapan's revenue from operations has been volatile, declining from ₹54.40 crores in FY2025 to ₹26.34 crores in FY2026, after growing from ₹26.91 crores in FY2024.
- · Yapan Bio was incorporated on 11th October 2019.
- · Yapan specializes in process development, characterization and Phase I/II GMP manufacturing services for vaccines and biologics.
- · The acquisition enables Piramal Pharma to embed Yapan's advanced large molecule capabilities into its integrated service offering.
- · The promoter/promoter group of Piramal Pharma is deemed indirectly interested in Yapan through the investment.
18-08-2026
Markolines Pavement Technologies Limited (MPTL) has received 'No Objection' letters from both BSE and NSE for its proposed Scheme of Amalgamation with Markolines Infra Limited (MIL), allowing the company to file the scheme with the NCLT. The observation letters, issued under Regulation 37 of SEBI LODR, include several compliance conditions such as ensuring all liabilities of MIL are transferred to MPTL, disclosing ongoing adjudication proceedings, and providing detailed financial and shareholding information to shareholders. The NSE's observation letter is valid for six months from August 17, 2026, within which the scheme must be submitted to the NCLT.
- · The NSE observation letter is valid for six months from August 17, 2026, requiring the scheme to be submitted to NCLT within that period.
- · SEBI's comments on the draft scheme include 18 specific conditions (a through r) covering compliance with LODR regulations, disclosure of ongoing adjudication, financials not older than 6 months, and mandatory demat form for any new equity shares.
- · The company must disclose the No-Objection letter on its website within 24 hours of receipt.
- · The company must complete listing and commence trading of securities within 60 days of receiving the NCLT order.
- · The exchange reserves the right to raise objections if information is found incomplete, incorrect, misleading, or false.
Get daily alerts with 8 investment signals, 9 risk alerts, 8 opportunities and full AI analysis of all 23 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India Sector Consolidation Regulatory Filings
August 10, 2026
India Sector Consolidation Regulatory Filings — August 10, 2026
August 08, 2026
India Sector Consolidation Regulatory Filings — August 08, 2026
August 07, 2026
India Sector Consolidation Regulatory Filings — August 07, 2026
August 06, 2026
India Sector Consolidation Regulatory Filings — August 06, 2026
🇮🇳 More from India
View all →August 11, 2026
India Pre-Market Regulatory Roundup — August 11, 2026
India Pre-Market Regulatory Roundup
August 11, 2026
India Quarterly Results BSE NSE Announcements — August 11, 2026
India Quarterly Results BSE NSE Announcements
August 11, 2026
India Upcoming Corporate Actions BSE NSE — August 11, 2026
India Upcoming Corporate Actions BSE NSE
August 11, 2026
India Merger Acquisition MCA Regulatory Filings — August 11, 2026
India Merger Acquisition MCA Regulatory Filings